secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0001140361-24-041102
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech reports updated VERSATILE-002 trial data: mOS 30 months, ORR 36%
----------------------------------------------------------------------------

- Median overall survival 30 months vs published 12-18 months for pembrolizumab alone.
- Objective response rate 36% (19/53); disease control rate 77% (41/53).
- 21% of patients (11/53) had 90-100% tumor shrinkage; 9% (5/53) complete response.
- Phase 3 VERSATILE-003 trial comparing combo vs pembrolizumab monotherapy planned to start in 2024.
- Treatment well tolerated; Grade ≥3 AEs in 9 patients (Grade 3 n=8, Grade 4 n=1).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036124041102/0001140361-24-041102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036124041102/ef20035887_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-041102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer